Saha Joy K, Xia Jinqi, Engle Steven K, Chen Yun-Fei, Glaesner Wolfgang, Jakubowski Joseph A
Eli Lilly and Company, BioTechnology Discovery Research, DC 0444, Lilly Corporate Center, Indianapolis, IN 46285, USA.
J Pharmacol Exp Ther. 2006 Mar;316(3):1159-64. doi: 10.1124/jpet.105.093534. Epub 2005 Nov 9.
A rodent model of controlled acute hyperglycemia that is sensitive to glucose-lowering agents insulin and glucagon-like peptide-1 (GLP-1) analog has been developed. The studies show that anesthesia could be induced in fasted rats with ketamine (100 mg/kg) plus a low dose of xylazine (5 mg/kg) without inducing the acute hyperglycemia typically associated with these agents. Under these conditions, continuous infusion of glucose (10 and 20%) via the jugular vein for 30 to 150 min induced hyperglycemia in a time-dependent fashion. Administration of "loading" boluses of glucose (0.2-0.6 ml of a 20% solution) prior to continuous infusion of 10% glucose produced more immediate and sustained hyperglycemia. Plasma levels of a variety of glucoregulatory and stress hormones such as insulin, growth hormone, glucagon, and corticosterone were determined. Only glucagon levels changed significantly during induction and maintenance of hyperglycemia. The infusion of insulin (0.1 U/kg/h) or GLP-1 analog (10 microg/kg/h) effectively lowered blood glucose from its elevated levels. Insulin produced a significant increase in glucagon levels, and GLP-1 analog produced a significant increase in insulin levels without any change in other glucoregulatory and stress hormone levels. In conclusion, the present studies identified a novel approach for the induction of anesthesia and surgical manipulations without inducing hyperglycemia and further defined an approach for producing acute hyperglycemia in a controlled fashion in rodents. This model will be beneficial to study the influence of hyperglycemia in acute models of critical illness where hyperglycemia develops following the precipitating event. This model was responsive to insulin and GLP-1 analog, both of which were effective in ameliorating hyperglycemia.
已建立一种对降血糖药物胰岛素和胰高血糖素样肽 -1(GLP -1)类似物敏感的可控急性高血糖啮齿动物模型。研究表明,禁食大鼠可通过氯胺酮(100 mg/kg)加低剂量赛拉嗪(5 mg/kg)诱导麻醉,而不会引发通常与这些药物相关的急性高血糖。在这些条件下,通过颈静脉持续输注葡萄糖(10%和20%)30至150分钟,会以时间依赖性方式诱导高血糖。在持续输注10%葡萄糖之前给予“负荷”葡萄糖推注(0.2 - 0.6 ml 20%溶液)会产生更即时和持续的高血糖。测定了多种葡萄糖调节和应激激素的血浆水平,如胰岛素、生长激素、胰高血糖素和皮质酮。只有胰高血糖素水平在高血糖诱导和维持期间有显著变化。输注胰岛素(0.1 U/kg/h)或GLP -1类似物(10 μg/kg/h)可有效降低升高的血糖水平。胰岛素使胰高血糖素水平显著升高,而GLP -1类似物使胰岛素水平显著升高,其他葡萄糖调节和应激激素水平无变化。总之,本研究确定了一种在不诱导高血糖的情况下诱导麻醉和进行手术操作的新方法,并进一步明确了一种在啮齿动物中以可控方式产生急性高血糖的方法。该模型将有助于研究在危重症急性模型中高血糖的影响,在这些模型中高血糖是在诱发事件后发生的。该模型对胰岛素和GLP -1类似物有反应,两者均能有效改善高血糖。